MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer

被引:116
|
作者
Ding, Lei [1 ,2 ]
Gu, Huan [1 ,2 ]
Xiong, Xianhui [1 ,2 ]
Ao, Hongshun [1 ,2 ]
Cao, Jiaqi [1 ,2 ]
Lin, Wen [1 ,2 ]
Yu, Min [1 ,2 ]
Lin, Jie [1 ,2 ]
Cui, Qinghua [1 ,2 ]
机构
[1] Yunnan Univ, Sch Life Sci, Lab Biochem & Mol Biol, Kunming 650091, Yunnan, Peoples R China
[2] Yunnan Educ Dept, Key Lab Mol Canc Biol, Kunming 650091, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
triple-negative breast cancer (TNBC); miRNAs; tumorigenesis; prognosis; chemotherapy and radiotherapy resistance; therapeutic strategies; epigenetic mechanisms; EPITHELIAL-MESENCHYMAL TRANSITION; DNA METHYLTRANSFERASES 3A; INHIBITS CELL-MIGRATION; LYMPH-NODE METASTASIS; DOWN-REGULATION; UP-REGULATION; STEM-CELLS; E-CADHERIN; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR;
D O I
10.3390/cells8121492
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Triple-negative breast cancer (TNBC) is the most aggressive, prevalent, and distinct subtype of breast cancer characterized by high recurrence rates and poor clinical prognosis, devoid of both predictive markers and potential therapeutic targets. MicroRNAs (miRNA/miR) are a family of small, endogenous, non-coding, single-stranded regulatory RNAs that bind to the 3 '-untranslated region (3 '-UTR) complementary sequences and downregulate the translation of target mRNAs as post-transcriptional regulators. Dysregulation miRNAs are involved in broad spectrum cellular processes of TNBC, exerting their function as oncogenes or tumor suppressors depending on their cellular target involved in tumor initiation, promotion, malignant conversion, and metastasis. In this review, we emphasize on masses of miRNAs that act as oncogenes or tumor suppressors involved in epithelial-mesenchymal transition (EMT), maintenance of stemness, tumor invasion and metastasis, cell proliferation, and apoptosis. We also discuss miRNAs as the targets or as the regulators of dysregulation epigenetic modulation in the carcinogenesis process of TNBC. Furthermore, we show that miRNAs used as potential classification, prognostic, chemotherapy and radiotherapy resistance markers in TNBC. Finally, we present the perspective on miRNA therapeutics with mimics or antagonists, and focus on the challenges of miRNA therapy. This study offers an insight into the role of miRNA in pathology progression of TNBC.
引用
收藏
页数:36
相关论文
共 50 条
  • [21] MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential (Review)
    Zhang, Kaiyuan
    Zhang, Yanlei
    Liu, Chang
    Xiong, Ying
    Zhang, Jiqiang
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (03) : 950 - 958
  • [22] Therapeutic targets of triple-negative breast cancer: a review
    Jamdade, Vinayak S.
    Sethi, Nikunj
    Mundhe, Nitin A.
    Kumar, Parveen
    Lahkar, Mangala
    Sinha, Neeraj
    BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (17) : 4228 - 4237
  • [23] The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer
    Kaur, Sukhmandeep
    Mendonca, Patricia
    Soliman, Karam F. A.
    NUTRIENTS, 2024, 16 (15)
  • [24] Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer
    Rhodes, Lyndsay V.
    Tilghman, Syreeta L.
    Boue, Stephen M.
    Wang, Shuchun
    Khalili, Hafez
    Muir, Shannon E.
    Bratton, Melyssa R.
    Zhang, Qiang
    Wang, Guangdi
    Burow, Matthew E.
    Collins-Burow, Bridgette M.
    ONCOLOGY LETTERS, 2012, 3 (01) : 163 - 171
  • [25] Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review
    Jie, Huan
    Ma, Wenhui
    Huang, Cong
    BREAST CANCER-TARGETS AND THERAPY, 2025, 17 : 265 - 274
  • [26] Circulating microRNAs and their role in the immune response in triple-negative breast cancer
    Pina-Sanchez, Patricia
    Valdez-Salazar, Hilda-Alicia
    Ruiz-Tachiquin, Martha-Eugenia
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [27] Analysis of the Clinicopathologic Features and Prognosis in Triple-Negative Breast Cancer
    Dehong Yang1 Hong Liu2 Jing Zhao21 Department of Surgery
    Chinese Journal of Clinical Oncology, 2008, (05) : 387 - 390
  • [28] TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer
    Wang, Kaijing
    Chai, Jia
    Xu, Junpeng
    Wei, Jie
    Li, Peifeng
    Liu, Yixiong
    Ma, Jing
    Xu, Tianqi
    Zhao, Danhui
    Yu, Kangjie
    Fan, Linni
    Yan, Qingguo
    Guo, Shuangping
    Li, Mingyang
    Wang, Zhe
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 226
  • [29] Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer
    Sai, Boya Manasa
    Dinakar, Yirivinti Hayagreeva
    Kumar, Hitesh
    Jain, Rupshee
    Kesharwani, Sharyu
    Kesharwani, Siddharth S.
    Mudavath, Shyam lal
    Ramkishan, Ajmeer
    Jain, Vikas
    THERAPEUTIC DELIVERY, 2024, 15 (11) : 871 - 891
  • [30] Novel therapeutic strategies for patients with triple-negative breast cancer
    Zhang, Jun-Fei
    Liu, Jia
    Wang, Yu
    Zhang, Bin
    ONCOTARGETS AND THERAPY, 2016, 9 : 6519 - 6528